Arterial Hypertension-clinical trials update 2023

Hypertens Res. 2023 Sep;46(9):2159-2167. doi: 10.1038/s41440-023-01359-y. Epub 2023 Jul 13.

Abstract

Arterial hypertension is associated with increased morbidity and mortality and research in the field is highly dynamic. This summary reviews the most important clinical trials published in 2022 and early 2023. Findings on new pharmacological approaches to treat resistant hypertension are presented and new knowledge about the optimal timing of the antihypertensive medication intake is discussed. It is focused on optimal blood pressure treatment targets and the problem of treatment and guideline inertia is acknowledged. Information about pregnancy-related hypertension is presented and blood pressure control following percutaneous thrombectomy after ischemic stroke is discussed. Finally, novel clinical data on device-based approaches to treat hypertension are summarized. The hypertension trials update summarizes the most important clincal trials on hypertension research in 2022 and early 2023. CTD - chlorthalidone, CV - cardiovascular, HCT - hydrochlorothiazide, SBP - systolic blood pressure, RDN - renal denervation *depicts systolic blood pressure only.

Keywords: Blood pressure; Device based therapies; Hypertension management; Resistant hypertension; Stroke; chronotherapy.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use
  • Blood Pressure
  • Chlorthalidone / pharmacology
  • Chlorthalidone / therapeutic use
  • Clinical Trials as Topic
  • Humans
  • Hypertension* / drug therapy
  • Kidney
  • Sympathectomy
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Chlorthalidone